Bilateral irreversible hearing loss associated with the combination of carboplatin and paclitaxel chemotherapy: A unusual side effect

Journal of Experimental and Clinical Cancer Research

Volumn 22, Issue 1, 2003, Pages 155-158

  Salvinelli, F ^a   Casale, M ^a   Vincenzi, Bruno ^a,b   Santini, D ^a   Di Peco, V ^a   Firrisi, L ^a   Onori, N ^a   Greco, F ^a   Tonini, G ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b Medical Oncology   (Italy)

Author keywords

Carboplatin; Chemotherapy; Hearing loss; Paclitaxel; Toxicity

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG EFFECT; FEMALE; HUMAN; LABORATORY TEST; NAUSEA; OTOTOXICITY; OVARY CARCINOMA; PERCEPTION DEAFNESS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUDIOMETRY; CARBOPLATIN; FEMALE; HEARING LOSS; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037349037     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. du Bois A.: Treatment of advanced ovarian cancer. Eur. J. Cancer 37: 1-7, 2001.
2. Fuchs D.A., Johnson R.K.: Cytologic evidence that paclitaxel, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison. Cancer Treat. Rep. 62:1219-1222, 1978.
3. Adams J.D., Flora K.P., Goldspiel B.R., Wilson J.W., Arbuck S.G., Finley R.: Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J. Natl. Cancer Inst. Monogr. 15:141-147, 1993.
4. Manfredi J.J., Horwitz S.B.: Paclitaxel: an antimitotic agent with a new mechanism of action. Pharmacol. Ther. 25: 83-125, 1984.
5. Horwitz S.B.: Taxol (paclitaxel): mechanisms of action. Ann. Oncol. 5: 3-6, 1994.
6. Kumar N.: Paclitaxel-induced polymerization of purified tubulin. J. Biol. Chem. 256: 10435-10441, 1981.
7. Schiff P.B., Fant J., and Horwitz S.B.: Promotion of microtubule assembly in vitro by Paclitaxel Nature 277: 665-667, 1979.
8. Thuret-Carnahan J., Bossu J.L., Feltz A., Langley K., Aunis D.: Effect of Paclitaxel on secretory cells: functional, morphological, and electrophysiological correlates. J. Cell. Biol.100: 1863-1874, 1985.
9. Piccart M.J., Lamb H., Vermorken J.B.: Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann. Oncol. 12: 1195-1203, 2001.
10. Vermorken J.B.: The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer. Int. J Gynecol. Cancer. 11: 21-30, 2001.
11. Lippman A.J., Helson C., Helson L., Krakoff I.H.: Clinical trials of cis-diamminedichloroplatinum (NSC-119875). Cancer Chemother. Rep. 57:191-200, 1973.
12. Forastiere A.A.: Overview of platinum chemotherapy in head and neck cancer. Semin. Oncol. 21: 49-52, 1994.
13. Roberts J.J., Friedlos F.: Quantitative aspects of the formation and loss of DNA interstrand crosslinks in Chinese hamster cells following treatment with cis-diamminedichloroplatinum(II) (cisplatin). I. Proportion of DNA-platinum reactions involved in DNA crosslinking. Biochim. Biophys. Acta. 655: 146-151, 1981.
14. Go R.S., Adjei A.A.: Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J. Clin. Oncol. 17: 409-422, 1999.
15. Nichols C.R., Tricot G., Williams S.D. et al.: Dose-intensive chemotherapy in refractory germ cell cancer: a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J. Clin. Oncol. 7: 932-939, 1989.
16. Paolozzi F.P., Gaver R., Poiesz B.J., et al.: Phase I-preliminary phase II trial of iproplatin, a cisplatin analogue Invest. New Drugs 6: 199-206, 1988.
17. van Zandwijk N., ten Bokkel Huinink W.W., et al.: Dose-finding studies with carboplatin, ifosfamide, etoposide, and mesna in non-small cell lung cancer. Semin. Oncol. 17: 16-19, 1990.
18. Bohm S., Oriana S., Spatti G., et al.: Dose intensification of platinum compounds with glutathione protection as induction chemotherapy for advanced ovarian carcinoma. Oncology 57(2):115-120, 1999.
19. Aydogdu I., Ozturan O., Kuku I., Kaya E., Sevinc A., Yildiz R.: Bilateral transient hearing loss associated with vincristine therapy: case report. J. Chemother. 12: 530-532, 2000.
20. De Lauretis A., De Capua B., Barbieri M.T., Bellussi L., Passali D.: ABR evaluation of ototoxicity in cancer patients receiving cisplatin or carboplatin. Scand. Audiol. 28:139-143, 1999.
21. Stern JW, Bunin N. Prospective study of carboplatin-based chemotherapy for pediatric germ cell tumors. Med. Pediatr. Oncol. Sep;39(3):163-167, 2002.
22. Tibaldi C, Pazzagli I, Berrettini S, De Vito A.: A case of ototoxicity in a patient with metastatic carcinoma of the breast treated with paclitaxel and vinorelbine. Eur. J. Cancer 34(7):1133-1134, 1998.
23. Gogas H, Shapiro F, Aghajanian C, Fennelly D, Almadrones L, Hoskins WJ, Spriggs DR.: The impact of diabetes mellitus on the toxicity of therapy for advanced ovarian cancer. Gynecol. Oncol. 61(1):22-26, 1996.
24. Husain K., Whitworth C., Somani S.M., Rybak L.P.: Carboplatin-induced oxidative stress in rat cochlea. Hear. Res. 159: 14-22, 2001.
25. Ding D.L., Wang J., Salvi R., et al.: Selective loss of inner hair cells and type-I ganglion neurons in carboplatin-treated chinchillas. Mechanisms of damage and protection. Ann. N. Y. Acad. Sci. 884:152-170, 1999.
26. Cavaletti G., Bogliun G., Zincone A., et al.: Neuro- and ototoxicity of high-dose carboplatin treatment in poor prognosis ovarian cancer patients. Anticancer Res. 5: 3797-3802, 1998.